{"id":"potassium-bicarbonate","_fda":{"id":"ba1639f4-e624-41da-a8d7-e97676b900d7","set_id":"8869554b-ff0b-4f0e-8a09-61e7be3b496e","openfda":{"unii":["HM5Z15LEBN"],"route":["ORAL"],"rxcui":["1111261","1111263","1111265","1111267"],"spl_id":["ba1639f4-e624-41da-a8d7-e97676b900d7"],"brand_name":["Effer-K 20 mEq Unflavored","Effer-K 20 mEq Orange Cream","Effer-K 10 mEq Unflavored","Effer-K 10 mEq Cherry Vanilla"],"spl_set_id":["8869554b-ff0b-4f0e-8a09-61e7be3b496e"],"package_ndc":["51801-013-30","51801-014-30","51801-011-30","51801-012-30"],"product_ndc":["51801-011","51801-013","51801-014","51801-012"],"generic_name":["POTASSIUM BICARBONATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["POTASSIUM BICARBONATE"],"manufacturer_name":["Nomax Inc."],"is_original_packager":[true]},"version":"4","warnings":["Warnings In patients with hyperkalemia and impaired mechanisms for excreting potassium the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment. Note: There is no conclusive evidence that potassium supplements lower blood pressure in hypertensive patients."],"pregnancy":["Usage in Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with Effer-K ® 10mEq or 20 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP). It is also not known whether these products can cause fetal harm when administered to pregnant women or can affect reproduction capacity. Effer-K ® 10mEq or 20mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) should be given to a pregnant woman only if clearly needed."],"overdosage":["Overdosage The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result (see Contraindications and Warnings ). It is important to recognize that initally hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest. Treatment measures for hyperkalemia include the elimination of foods and medications containing potassium and potassium-sparing diuretics, as well as ACE inhibitors, beta blocking agents, NSAIDs, heparin, and cyclosporine. In cases of life-threatening hyperkalemia, treatment measures may include: (1) intravenous administration of 300 to 500 ml/hr of 10% dextrose solution containing 10-20 units of insulin per 1,000 ml; (2) correction of acidosis, if present, with intravenous sodium bicarbonate; (3) use of exchange resins, hemodialysis, or peritoneal dialysis; (4) administration of a calcium salt to antagonize the cardiotoxic effects in patients whose electrocardiograms show appropriate characteristics, and who are not receiving digitalis glycosides; and (5) maintenance of a high urine output in suitable patients. In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, rapid lowering of serum potassium can produce digitalis toxicity."],"description":["Description Effer-K ® 10mEq and 20 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) are intended for the preparation of an oral solution of potassium. Each 10 mEq tablet contains 1.0g potassium bicarbonate and 0.84g citric acid which, after effervescing, provides a solution containing 10 mEq (391 mg) of elemental potassium as potassium citrate. Each 20 mEq tablet contains 2.0g potassium bicarbonate and 1.68g citric acid which, after effervescing, provides a solution containing 20 mEq (782 mg) of elemental potassium as potassium citrate. Tablets also contain maltodextrin, anhydrous dextrose and l-leucine. In addition, the flavored tablets contain SD flavors, and sucralose. The 10 mEq Cherry Vanilla tablets contain FD&C Red #40 and the 20 mEq Orange Cream tablets contain FD&C Yellow #6 and FD&C Red #40. The Unflavored 10 and 20 mEq tablets do not contain any natural or synthetic dyes, flavors or sweeteners. The 10 mEq tablets are 11/16 inch diameter round, flat face on both sides with large bevels. EK 10 is imprinted on one side. The 20 mEq tablets are 7/8 inch diameter round, flat face on both sides with large bevels. EK 20 is imprinted on one side. Each tablet is pouched with the product description on one side of the pouch and the lot number, expiration date and bar code on the other"],"precautions":["Precautions The diagnosis of potassium depletion is ordinarily made by demonstrating hypokalemia in a patient with a clinical history suggesting some cause for potassium depletion. In interpreting the serum potassium level, the physician should bear in mind that acute alkalosis per se can produce hypokalemia in the absence of a deficit in total body potassium, while acute acidosis per se can increase the serum potassium concentration into the normal range even in the presence of a reduced total body potassium. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram, and the clinical status of the patient. Information for patients To minimize the possibility of gastrointestinal irritation associated with the oral ingestion of concentrated potassium salt preparations, patients should be directed to dissolve each dose completely in the stated amount of water. Each dose should be taken immediately after a meal or with food. Patients should avoid low-salt foods and salt substitutes, unless approved by physician. The patient should be cautioned to comply strictly with the regimen, particularly when taking diuretics or digitalis, to visit the physician regularly and to report at once any unusual symptoms (e.g. blackish stools, a sign of gastrointestinal bleeding). As with any other medicine, the patient should be counseled on this background information and advised to report to the physician any changes in routine (e.g. starting a fitness program). Proper storage and handling of the product is important. Tablets should not be removed from foil pouch until shortly before use. Laboratory tests Frequent clinical evaluation of the patient should include an ECG and a serum potassium level; also, as appropriate, renal function, serum magnesium and serum pH. Drug Interactions The simultaneous administration of potassium supplements and a potassium-sparing diuretic can produce severe hyperkalemia (see Contraindications ). Potassium supplements should be used cautiously in patients who are using salt substitutes, because most of the latter contain substantial amounts of potassium. Such concomitant use could result in hyperkalemia. Moreover, the following drugs may produce unfavorable interactions when used concomitantly with potassium supplements: angiotension-converting enzyme (ACE) inhibitors, nonsteroid anti-inflammatory drugs (NSAIDs), beta-adrenergic blocking drugs, heparin, low-salt foods, other potassium containing medications, digitalis glycosides and others. Carcinogenesis, Mutagenesis, Impairment of Fertility Potassium is an essential constituent of the human diet. There are no data available on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility in animals or in human beings. Usage in Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with Effer-K ® 10mEq or 20 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP). It is also not known whether these products can cause fetal harm when administered to pregnant women or can affect reproduction capacity. Effer-K ® 10mEq or 20mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) should be given to a pregnant woman only if clearly needed. Labor and Delivery Information unknown. Nursing Mothers Although no studies have been done, it is presumed that potassium is excreted in human milk. Caution should be exercised when Effer-K ® 10mEq or 20mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) are administered to a nursing woman. Usage in Children Safety and effectiveness in children have not been established."],"how_supplied":["How Supplied Each tablet of Effer-K ® 10 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) in solution provides 10 mEq (391 mg) of elemental potassium as potassium citrate. Each tablet of Effer-K ® 20 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) in solution provides 20 mEq (782 mg) of elemental potassium as potassium citrate. Store below 40°C (104°F), preferably between 15° and 30°C (59° and 86°F), in original hermetic package. The 10 mEq tablets are 11/16 inch diameter round, flat face on both sides with large bevels. EK 10 is imprinted on one side of the tablet. Each tablet is pouched with the product description on one side of the pouch and the lot number, expiration date and barcode on the other. The 20 mEq tablets are 7/8 inch diameter round, flat face on both sides with large bevels. EK 20 is imprinted on one side of the tablet. Each tablet is pouched with the product description on one side of the pouch and the lot number, expiration date and barcode on the other. NDC 51801-01330 Unflavored, 10 mEq, package of 30 tablets NDC 51801-01430 Cherry Vanilla, 10 mEq, package of 30 tablets NDC 51801-01130 Unflavored, 20 mEq, package of 30 tablets NDC 51801-01230 Orange Cream, 20 mEq, package of 30 tablets Nomax, Inc. St. Louis, MO 63123 - Made in USA MSN 015-183 Rev. 05/12"],"pediatric_use":["Usage in Children Safety and effectiveness in children have not been established."],"effective_time":"20191218","nursing_mothers":["Nursing Mothers Although no studies have been done, it is presumed that potassium is excreted in human milk. Caution should be exercised when Effer-K ® 10mEq or 20mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) are administered to a nursing woman."],"laboratory_tests":["Laboratory tests Frequent clinical evaluation of the patient should include an ECG and a serum potassium level; also, as appropriate, renal function, serum magnesium and serum pH."],"adverse_reactions":["Adverse Reactions One of the most severe adverse effects is hyperkalemia (see Contraindications , Warnings and Overdosage ). The most common adverse reactions to oral potassium salts are nausea, vomiting, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals, or reducing the dose. Skin rash has been reported rarely."],"contraindications":["Contraindications Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Conditions predisposing to hyperkalemia include: chronic renal failure, acute metabolic acidosis, uncontrolled diabetes mellitus, esophageal compression or delayed gastric emptying or intestinal obstruction/stricture or peptic ulcer. Potassium supplements should be used with caution and only where medically indicated in patients with familial periodic paralysis, myotonia congenita or severe/complete heart block. IMPORTANT: Potassium supplements are contraindicated in patients receiving potassium-sparing diuretics (e.g. spironolactone, triamterene) since such use may produce severe hyperkalemia."],"drug_interactions":["Drug Interactions The simultaneous administration of potassium supplements and a potassium-sparing diuretic can produce severe hyperkalemia (see Contraindications ). Potassium supplements should be used cautiously in patients who are using salt substitutes, because most of the latter contain substantial amounts of potassium. Such concomitant use could result in hyperkalemia. Moreover, the following drugs may produce unfavorable interactions when used concomitantly with potassium supplements: angiotension-converting enzyme (ACE) inhibitors, nonsteroid anti-inflammatory drugs (NSAIDs), beta-adrenergic blocking drugs, heparin, low-salt foods, other potassium containing medications, digitalis glycosides and others."],"labor_and_delivery":["Labor and Delivery Information unknown."],"clinical_pharmacology":["Clinical Pharmacology Potassium ion is the principal intracellular cation of most body tissues, whereas sodium ion is relatively low in concentration. In extracellular fluid the opposite exists, sodium ion being principal and potassium ion being low. The situation is maintained by an active membrane-bound enzyme (Na + K + ATPase). This potassium ion concentration gradient is essential to conduct nerve impulses in such specialized tissues as the brain, heart, and skeletal muscle; and in addition, to maintain normal renal function, acid-base balance, and various cellular metabolic functions. Elimination values are 90% renal and 10% fecal. Potassium depletion may occur if the rate of potassium ion loss by renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium ion intake. Such depletion usually develops slowly as a consequence of prolonged therapy with oral diuretics, primary or secondary hyperaldosteronism, diabetic ketoacidosis, severe diarrhea, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Potassium depletion due to these causes is usually accompanied by a concomitant deficiency of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, mood or mental changes, nausea, vomiting, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and in advanced cases flaccid paralysis and/or impaired ability to concentrate urine."],"indications_and_usage":["Indications and Usage For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassium-losing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated."],"information_for_patients":["Information for patients To minimize the possibility of gastrointestinal irritation associated with the oral ingestion of concentrated potassium salt preparations, patients should be directed to dissolve each dose completely in the stated amount of water. Each dose should be taken immediately after a meal or with food. Patients should avoid low-salt foods and salt substitutes, unless approved by physician. The patient should be cautioned to comply strictly with the regimen, particularly when taking diuretics or digitalis, to visit the physician regularly and to report at once any unusual symptoms (e.g. blackish stools, a sign of gastrointestinal bleeding). As with any other medicine, the patient should be counseled on this background information and advised to report to the physician any changes in routine (e.g. starting a fitness program). Proper storage and handling of the product is important. Tablets should not be removed from foil pouch until shortly before use."],"dosage_and_administration":["Dosage and administration Effer-K ® 10 mEq. Adults - one tablet (Cherry Vanilla or Unflavored) each containing 10 mEq. (391 mg) of elemental potassium, 1 to 4 times daily, depending on the requirement of the patient. Completely dissolve the Cherry Vanilla flavored tablet in 2 to 3 ounces (58 to 85 mL) of cold or ice water before drinking. Completely dissolve the Unflavored tablet in 2 to 3 ounces (58 to 85 mL) of cold juice of choice before drinking. Effer-K ® 20 mEq. Adults - one tablet (Orange Cream or Unflavored) each containing 20 mEq. (782 mg) of elemental potassium, 1 to 4 times daily, depending on the requirement of the patient. Completely dissolve the Orange Cream flavored tablet in 3 to 4 ounces (85 to 115 mL) of cold or ice water before drinking. Completely dissolved the Unflavored tablet in 3 to 4 ounces (85 to 115 mL) of cold juice of choice before drinking. NOTE: It is suggested that any effervescent potassium tablet be taken with meals and sipped slowly over a 5 to 10 minute period."],"spl_product_data_elements":["Effer-K 10 mEq Unflavored POTASSIUM BICARBONATE POTASSIUM BICARBONATE POTASSIUM CATION CITRIC ACID MONOHYDRATE MALTODEXTRIN DEXTROSE LEUCINE EK;10 Effer-K 10 mEq Cherry Vanilla POTASSIUM BICARBONATE POTASSIUM BICARBONATE POTASSIUM CATION CITRIC ACID MONOHYDRATE MALTODEXTRIN DEXTROSE LEUCINE EK;10 Cherry Vanilla Effer-K 20 mEq Unflavored POTASSIUM BICARBONATE POTASSIUM BICARBONATE POTASSIUM CATION CITRIC ACID MONOHYDRATE MALTODEXTRIN DEXTROSE LEUCINE EK;20 Effer-K 20 mEq Orange Cream POTASSIUM BICARBONATE POTASSIUM BICARBONATE POTASSIUM CATION CITRIC ACID MONOHYDRATE MALTODEXTRIN DEXTROSE LEUCINE EK;20 Orange Cream"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 10mEq Tablet Pouch Carton - Unflavored NDC 51801-013-30 30 Tablets Effer-K ® 10mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 10mEq (391mg) of potassium in solution as potassium citrate. Unflavored Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 10mEq Tablet Pouch Carton - Unflavored","PRINCIPAL DISPLAY PANEL - 10 mEq Tablet Pouch Carton - Cherry Vanilla NDC 51801-014-30 30 Tablets Effer-K ® 10 mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 10mEq (391mg) of potassium in solution as potassium citrate. Cherry Vanilla Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 10 mEq Tablet Pouch Carton - Cherry Vanilla","PRINCIPAL DISPLAY PANEL - 20 mEq Tablet Pouch Carton - Unflavored NDC 51801-011-30 30 Tablets Effer-K ® 20 mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 20mEq (782mg) of potassium in solution as potassium citrate. Unflavored Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 20 mEq Tablet Pouch Carton - Unflavored","PRINCIPAL DISPLAY PANEL - 20mEq Tablet Pouch Carton - Orange Cream NDC 51801-012-30 30 Tablets Effer-K ® 20mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 20mEq (782mg) of potassium in solution as potassium citrate. Orange Cream Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 20mEq Tablet Pouch Carton - Orange Cream"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Potassium is an essential constituent of the human diet. There are no data available on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility in animals or in human beings."]},"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"potassium-sparing diuretic","severity":"major","mechanism":"concurrent use increases potassium levels","management":"avoid concurrent use; monitor potassium levels closely if co-administration is necessary","clinicalEffect":"severe hyperkalemia"},{"drug":"salt substitutes","severity":"moderate","mechanism":"most salt substitutes contain substantial amounts of potassium","management":"use potassium supplements cautiously; monitor potassium levels","clinicalEffect":"hyperkalemia"},{"drug":"angiotensin-converting enzyme (ACE) inhibitors","severity":"moderate","mechanism":"concurrent use may increase potassium levels","management":"monitor potassium levels; adjust dosages as needed","clinicalEffect":"unfavorable interactions"},{"drug":"nonsteroidal anti-inflammatory drugs (NSAIDs)","severity":"moderate","mechanism":"concurrent use may increase potassium levels","management":"monitor potassium levels; adjust dosages as needed","clinicalEffect":"unfavorable interactions"},{"drug":"beta-adrenergic blocking drugs","severity":"moderate","mechanism":"concurrent use may increase potassium levels","management":"monitor potassium levels; adjust dosages as needed","clinicalEffect":"unfavorable interactions"},{"drug":"heparin","severity":"moderate","mechanism":"concurrent use may increase potassium levels","management":"monitor potassium levels; adjust dosages as needed","clinicalEffect":"unfavorable interactions"},{"drug":"low-salt foods","severity":"minor","mechanism":"may affect potassium balance","management":"monitor potassium levels; adjust diet as needed","clinicalEffect":"unfavorable interactions"},{"drug":"other potassium-containing medications","severity":"moderate","mechanism":"concurrent use increases potassium levels","management":"monitor potassium levels; adjust dosages as needed","clinicalEffect":"unfavorable interactions"},{"drug":"digitalis glycosides","severity":"moderate","mechanism":"concurrent use may increase risk of toxicity due to hyperkalemia","management":"monitor potassium levels; adjust dosages as needed","clinicalEffect":"unfavorable interactions"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"50%","severity":"common","organSystem":""},{"effect":"Abdominal fullness","drugRate":"50%","severity":"common","organSystem":""},{"effect":"Bloating","drugRate":"50%","severity":"common","organSystem":""},{"effect":"Abdominal cramps","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Anal irritation","drugRate":"","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Anaphylactic reaction","drugRate":"","severity":"serious"},{"effect":"Upper GI bleeding from Mallory-Weiss Tear","drugRate":"","severity":"serious"},{"effect":"Esophageal perforation","drugRate":"","severity":"serious"},{"effect":"Asystole","drugRate":"","severity":"serious"},{"effect":"Sudden dyspnea with pulmonary edema","drugRate":"","severity":"serious"},{"effect":"Cardiac Arrhythmias","drugRate":"","severity":"serious"},{"effect":"Seizures","drugRate":"","severity":"serious"},{"effect":"Colonic Mucosal Ulcerations","drugRate":"","severity":"serious"},{"effect":"Ischemic Colitis","drugRate":"","severity":"serious"},{"effect":"Aspiration","drugRate":"","severity":"serious"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=POTASSIUM BICARBONATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:12:30.778418+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:14:27.124860+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:12:36.392777+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=POTASSIUM BICARBONATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:12:36.722320+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:12:29.671893+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:14:21.951245+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:12:29.671921+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:13:29.704804+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2106975/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:12:37.847523+00:00"}},"_dailymed":{"setId":"27195187-75a3-431f-90d9-84da1b94e849","title":"GAVILYTE-N (POLYETHYLENE GLYCOL-3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE AND SODIUM BICARBONATE) POWDER, FOR SOLUTION [LUPIN PHARMACEUTICALS,INC.]"},"aiSummary":"Potassium bicarbonate is a marketed drug primarily indicated for the treatment of hypokalemia. The key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following patent expiry.","_scrapedAt":"2026-03-28T02:05:32.323Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T06:14:27.124945+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"potassium-bicarbonate-hypokalemia","name":"Hypokalemia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with hypokalemia with or without metabolic alkalosis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with hypokalemia with or without metabolic alkalosis","diagnosticRequired":null,"brandNameForIndication":""},{"id":"potassium-bicarbonate-chronic-digitalis-intoxication","name":"Chronic Digitalis Intoxication","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with chronic digitalis intoxication","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with chronic digitalis intoxication","diagnosticRequired":null,"brandNameForIndication":""},{"id":"potassium-bicarbonate-hypokalemic-familial-periodic-","name":"Hypokalemic Familial Periodic Paralysis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with hypokalemic familial periodic paralysis","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with hypokalemic familial periodic paralysis","diagnosticRequired":null,"brandNameForIndication":""},{"id":"potassium-bicarbonate-prevention-of-potassium-deplet","name":"Prevention of Potassium Depletion - Digitalis and Diuretics","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients receiving digitalis and diuretics for congestive heart failure","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients receiving digitalis and diuretics for congestive heart failure","diagnosticRequired":null,"brandNameForIndication":""},{"id":"potassium-bicarbonate-prevention-of-potassium-deplet","name":"Prevention of Potassium Depletion - Hepatic Cirrhosis with Ascites","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with hepatic cirrhosis with ascites","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with hepatic cirrhosis with ascites","diagnosticRequired":null,"brandNameForIndication":""},{"id":"potassium-bicarbonate-prevention-of-potassium-deplet","name":"Prevention of Potassium Depletion - Aldosterone Excess","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with states of aldosterone excess with normal renal function","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with states of aldosterone excess with normal renal function","diagnosticRequired":null,"brandNameForIndication":""},{"id":"potassium-bicarbonate-prevention-of-potassium-deplet","name":"Prevention of Potassium Depletion - Potassium-Losing Nephropathy","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with potassium-losing nephropathy","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with potassium-losing nephropathy","diagnosticRequired":null,"brandNameForIndication":""},{"id":"potassium-bicarbonate-prevention-of-potassium-deplet","name":"Prevention of Potassium Depletion - Diarrheal States","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with certain diarrheal states","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with certain diarrheal states","diagnosticRequired":null,"brandNameForIndication":""},{"id":"potassium-bicarbonate-prevention-of-potassium-deplet","name":"Prevention of Potassium Depletion - Corticosteroid Therapy","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients undergoing long-term corticosteroid therapy","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients undergoing long-term corticosteroid therapy","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT07494266","phase":"NA","title":"Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited Potassium Content in Patients With Chronic Kidney Disease: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Karolinska Institutet","startDate":"2026-04-10","conditions":"Hyperkalemia, Chronic Kidney Disease (Stages 4 and 5)","enrollment":30},{"nctId":"NCT01915212","phase":"PHASE1","title":"Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-09-26","conditions":"Healthy Volunteers","enrollment":69},{"nctId":"NCT07497893","phase":"NA","title":"FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2026-12-01","conditions":"Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper)","enrollment":1000},{"nctId":"NCT00931463","phase":"PHASE4","title":"A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-09","conditions":"HIV Infections","enrollment":558},{"nctId":"NCT07493798","phase":"","title":"Serum Potassium Prediction Using Machine Learning and Single-lead ECG","status":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-20","conditions":"Infection, Heart Failure, Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT06561711","phase":"PHASE4","title":"Optimization of Minocycline for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-21","conditions":"Helicobacter Pylori Infection","enrollment":480},{"nctId":"NCT07171203","phase":"PHASE1","title":"Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-06","conditions":"Gastrointestinal Stromal Tumors","enrollment":18},{"nctId":"NCT07492134","phase":"PHASE2","title":"APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-04-01","conditions":"Acute Uncomplicated Diverticulitis","enrollment":100},{"nctId":"NCT06977841","phase":"NA","title":"Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2025-06-10","conditions":"Helicobacter Pylori Eradication, Adverse Reaction","enrollment":640},{"nctId":"NCT05568498","phase":"PHASE2","title":"Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-01-20","conditions":"Parkinson Disease, Depression, PARKINSON DISEASE (Disorder)","enrollment":60},{"nctId":"NCT05761080","phase":"PHASE4","title":"Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics","status":"RECRUITING","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2021-04-22","conditions":"Laparoscopic Appendectomy, Complicated Appendicitis, Periappendicular Abscess","enrollment":772},{"nctId":"NCT07054905","phase":"","title":"Prediction of Hyperkalemia in Dialysis Patients Through Waveform Analysis Using Wearable ECG","status":"COMPLETED","sponsor":"Kyungho Park","startDate":"2025-06-23","conditions":"Hyperkalemia, Chronic Kidney Disease","enrollment":32},{"nctId":"NCT04896281","phase":"NA","title":"Phenylalanine-free Diet for Patients With Secondary Hyperphenylalaninemia in ICU","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-07-30","conditions":"Non-Phenylketonuric Hyperphenylalaninemia","enrollment":100},{"nctId":"NCT06956599","phase":"PHASE3","title":"Hypersensitivity Reduction Efficacy: 5% Potassium Nitrate Toothpaste Compared to Colgate Cavity Protection Toothpaste","status":"COMPLETED","sponsor":"Colgate Palmolive","startDate":"2025-05-10","conditions":"Dentin Hypersensitivity","enrollment":80},{"nctId":"NCT06287372","phase":"","title":"Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia","status":"COMPLETED","sponsor":"Damascus University","startDate":"2022-07-04","conditions":"Myocardial Injury, Cardiac Surgery, Myocardial Protection","enrollment":20},{"nctId":"NCT07483736","phase":"PHASE3","title":"Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients.","status":"NOT_YET_RECRUITING","sponsor":"Versailles Hospital","startDate":"2026-03","conditions":"C15.378","enrollment":1526},{"nctId":"NCT06678685","phase":"PHASE2, PHASE3","title":"Spironolactone Improved Children With Gene Mutations Related to NCOR","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-10-30","conditions":"NCOR Gene Mutations, Spironolactone, ASD","enrollment":2},{"nctId":"NCT06244290","phase":"PHASE3","title":"Dentinal Hypersensitivity Reduction","status":"COMPLETED","sponsor":"Colgate Palmolive","startDate":"2020-09-28","conditions":"Dentinal Hypersensitivity","enrollment":123},{"nctId":"NCT07469722","phase":"PHASE2, PHASE3","title":"POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2026-03-23","conditions":"Acute Heart Failure (AHF), Congestive Heart Failure Acute, Diuretic Effect","enrollment":128},{"nctId":"NCT07478640","phase":"PHASE3","title":"Bioadhesive Film of Acmella Oleracea (Jambu) in the Reduction of Post-bleaching Dental Sensitivity Caused by Bleaching With 35% Hydrogen Peroxide.","status":"COMPLETED","sponsor":"Universidade Federal do Para","startDate":"2024-04-01","conditions":"Tooth Sensitivity, Teeth Whitening","enrollment":72},{"nctId":"NCT07429201","phase":"NA","title":"Comparing an Electrolyte-Carbohydrate Beverage to Water During Ramadan","status":"COMPLETED","sponsor":"PepsiCo Global R&D","startDate":"2026-02-11","conditions":"Hydration Status, Dietary Intake","enrollment":60},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":"Gastric Cancer","enrollment":226},{"nctId":"NCT05558267","phase":"NA","title":"Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2027-01-15","conditions":"End Stage Kidney Disease","enrollment":20},{"nctId":"NCT07467213","phase":"PHASE4","title":"Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2026-04-01","conditions":"Acute Myocardial Infarction (AMI), Gastrointestinal Bleeding","enrollment":5000},{"nctId":"NCT07460882","phase":"NA","title":"The Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04-01","conditions":"Hypertension","enrollment":607},{"nctId":"NCT02627196","phase":"NA","title":"Baroreflex Activation Therapy for Heart Failure","status":"COMPLETED","sponsor":"CVRx, Inc.","startDate":"2016-04-19","conditions":"Heart Failure","enrollment":1090},{"nctId":"NCT06953986","phase":"NA","title":"A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks","status":"RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2025-12-20","conditions":"GERD","enrollment":414},{"nctId":"NCT06750653","phase":"PHASE4","title":"Skin Barrier Function and Inflammation in Aging: The BIA Study","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-02-06","conditions":"Inflammation, Skin Inflammation, Aging","enrollment":32},{"nctId":"NCT04102371","phase":"PHASE3","title":"Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-08-25","conditions":"Shock, Septic","enrollment":9041},{"nctId":"NCT07451171","phase":"PHASE2","title":"Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":"Small Intestine Bacterial Overgrowth","enrollment":60},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":"Acute Aluminum Phosphide Poisoned Cases","enrollment":74},{"nctId":"NCT04101188","phase":"NA","title":"Mechanisms Underlying the Protective Vascular Effects of Dietary Potassium in Humans","status":"RECRUITING","sponsor":"University of Delaware","startDate":"2020-01-16","conditions":"Cardiovascular Risk Factor","enrollment":90},{"nctId":"NCT07196865","phase":"NA","title":"Comparison of the Clinical Effects of Open, Closed, and Semi-close Hemorrhoidectomy.","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Putian University","startDate":"2026-04-01","conditions":"Hemorrhoids","enrollment":378},{"nctId":"NCT06835829","phase":"NA","title":"Comparing Advanced Hemostasis and Ultrasound-Guided Puncture to Conventional Approaches in Distal Radial Access","status":"RECRUITING","sponsor":"Associazione per lo Studio delle Malattie Cardiovascolari Cardiva ONLUS","startDate":"2025-12-31","conditions":"Coronary Catheterization","enrollment":480},{"nctId":"NCT07284069","phase":"EARLY_PHASE1","title":"Senicapoc and Perampanel for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2026-03-01","conditions":"Glioblastoma","enrollment":36},{"nctId":"NCT06076304","phase":"PHASE4","title":"Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis","status":"RECRUITING","sponsor":"Daniel Merenstein","startDate":"2023-11-21","conditions":"Sinus Infection, Acute Sinusitis","enrollment":3720},{"nctId":"NCT07447583","phase":"NA","title":"Traditional vs. Minimally Invasive Decay Treatments in Primary Molars: An 18-month Split-mouth Randomized Study","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2024-08-01","conditions":"Dental Caries","enrollment":60},{"nctId":"NCT06494072","phase":"PHASE4","title":"Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-08-22","conditions":"Community Acquired Pneumonia in Children","enrollment":236},{"nctId":"NCT07442448","phase":"PHASE4","title":"Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure","status":"ENROLLING_BY_INVITATION","sponsor":"Cathay General Hospital","startDate":"2026-04","conditions":"Heart Failure and Preserved Ejection Fraction, Heart Failure, Heart Failure and Mildly Reduced Ejection Fraction","enrollment":40},{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":"Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic","enrollment":200},{"nctId":"NCT07435714","phase":"NA","title":"Facilitating Surgical Choice in Patient With Chronic Hypertrophic Rhinitis Using a Patient Decision Aid","status":"NOT_YET_RECRUITING","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2026-02-01","conditions":"Allergic Rhinitis","enrollment":158},{"nctId":"NCT07437768","phase":"NA","title":"Vonoprazan Test for PPI Refractory GERD","status":"ENROLLING_BY_INVITATION","sponsor":"Fu Jen Catholic University Hospital","startDate":"2025-12-24","conditions":"Refractory GERD, NERD, PCAB","enrollment":100},{"nctId":"NCT07437430","phase":"NA","title":"Evaluation of Food Additive Contributions to Obesity: Pilot Study 1","status":"RECRUITING","sponsor":"McMaster University","startDate":"2026-02-10","conditions":"Obesity (Disorder)","enrollment":20},{"nctId":"NCT06393049","phase":"NA","title":"Microdialysis and Jugular Bulb Glucose Profiles During Hyperglycaemic Clamping in Patients With Severe Acute Brain Injury","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2024-05-08","conditions":"Acute Brain Injury","enrollment":14},{"nctId":"NCT07029503","phase":"PHASE2","title":"Swedish Cardiac And Renal Failure Study-1","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2026-02","conditions":"HFrEF - Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease","enrollment":40},{"nctId":"NCT07221448","phase":"NA","title":"Sodium vs Potassium Education to Improve Vascular Health","status":"RECRUITING","sponsor":"Florida State University","startDate":"2026-03-02","conditions":"Healthy","enrollment":32},{"nctId":"NCT06624956","phase":"PHASE4","title":"Prevention and Treatment of Common Hyperglycemia in Surgery Pilot","status":"COMPLETED","sponsor":"University of Washington","startDate":"2024-09-04","conditions":"Surgery, Non Diabetic Hyperglycemia","enrollment":106},{"nctId":"NCT07422974","phase":"","title":"Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer","status":"RECRUITING","sponsor":"Osijek University Hospital","startDate":"2026-01-09","conditions":"Colorectal Carcinoma (CRC), Complications, Neoadjuvant Therapy","enrollment":68},{"nctId":"NCT07419763","phase":"NA","title":"Intra Oral Appliance (IOA) Model Evaluating the Efficacy of Sensitive Toothpaste","status":"COMPLETED","sponsor":"Church & Dwight Company, Inc.","startDate":"2025-04-15","conditions":"Dental Caries","enrollment":30},{"nctId":"NCT05425030","phase":"NA","title":"A Community Health Worker-Led LSSS Intervention in Bangladesh","status":"COMPLETED","sponsor":"Stanford University","startDate":"2023-01-26","conditions":"Blood Pressure, Hypertension","enrollment":618},{"nctId":"NCT06811363","phase":"","title":"Contribution of Bone to Urine Citrate","status":"ENROLLING_BY_INVITATION","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02-28","conditions":"Osteoporosis","enrollment":25},{"nctId":"NCT06094920","phase":"PHASE4","title":"Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2024-07-29","conditions":"Diabetes Mellitus Type 2 With Proteinuria, Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":12},{"nctId":"NCT04966507","phase":"PHASE2","title":"Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-02-17","conditions":"Gonorrhea","enrollment":89},{"nctId":"NCT07059065","phase":"NA","title":"FIBERGRAFT Aeridyan Posterolateral Fusion Study","status":"RECRUITING","sponsor":"DePuy Synthes Products, Inc.","startDate":"2025-08-15","conditions":"Degenerative Spine Disease","enrollment":316},{"nctId":"NCT04651088","phase":"EARLY_PHASE1","title":"Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-07-01","conditions":"Kidney Stone","enrollment":15},{"nctId":"NCT07293910","phase":"PHASE2","title":"Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-15","conditions":"HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection, Helicobacter Pylori Gastrointestinal Tract Infection","enrollment":66},{"nctId":"NCT06731270","phase":"PHASE2","title":"Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-04-09","conditions":"Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":20},{"nctId":"NCT06366230","phase":"PHASE1, PHASE2","title":"Adding Urea to the Final Dialysis Fluid","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-16","conditions":"Dysequilibrium Syndrome, ESRD, Hyperkalemia","enrollment":20},{"nctId":"NCT07408076","phase":"PHASE1, PHASE2","title":"Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones","status":"NOT_YET_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2026-02-01","conditions":"Kidney Stones, Urolithiasis, Hypocitraturia, Nephrolithiasis","enrollment":30},{"nctId":"NCT07405684","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp First-line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":544},{"nctId":"NCT07405697","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp Rescue Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"Helicobacter Pylori Infection","enrollment":290},{"nctId":"NCT03253172","phase":"NA","title":"Potassium Supplementation in CKD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2017-07-01","conditions":"Renal Insufficiency, Chronic, Potassium Depletion, Hypertension","enrollment":532},{"nctId":"NCT07023315","phase":"PHASE3","title":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-08-14","conditions":"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":760},{"nctId":"NCT07403305","phase":"NA","title":"The Effect of Water Physical Exercise Program in Thermal Water and Hydropinotherapy on Cardiovascular Health","status":"NOT_YET_RECRUITING","sponsor":"Instituto Politécnico de Bragança","startDate":"2026-01-19","conditions":"Cardiovascular (CV) Risk","enrollment":80},{"nctId":"NCT06381934","phase":"NA","title":"Validation of New Diagnostic Indices to Simplify Hyponatremia Therapy Assessment in Patients on Thiazide Diuretics","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-05-06","conditions":"Thiazide Associated Hyponatremia","enrollment":136},{"nctId":"NCT07400016","phase":"NA","title":"Efficacy of Superoxide Dismutase Spray in Preventing Radiation Dermatitis in Patients With Head and Neck Cancer .","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02-10","conditions":"Radiation Dermatitis","enrollment":140},{"nctId":"NCT04856488","phase":"PHASE3","title":"Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter","status":"RECRUITING","sponsor":"Jan Calissendorff","startDate":"2021-11-18","conditions":"Hyperthyroidism","enrollment":182},{"nctId":"NCT06819111","phase":"PHASE1","title":"Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-07-01","conditions":"Kidney Calculi","enrollment":20},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT07215767","phase":"PHASE3","title":"Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice","status":"RECRUITING","sponsor":"HALEON","startDate":"2025-09-16","conditions":"Dentin Hypersensitivity","enrollment":850},{"nctId":"NCT07389837","phase":"NA","title":"Maple Syrup Carbohydrate Dose-Response on 20-km Cycling Time-Trial Performance","status":"NOT_YET_RECRUITING","sponsor":"Université de Montréal","startDate":"2026-02-01","conditions":"Exercise, Endurance Cycling Performance, Carbohydrate Intolerance","enrollment":32},{"nctId":"NCT06920914","phase":"NA","title":"Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-07-01","conditions":"Chronic Kidney Disease","enrollment":48},{"nctId":"NCT05844501","phase":"PHASE4","title":"Ondansetron for the Management of Atrial Fibrillation","status":"RECRUITING","sponsor":"Indiana University","startDate":"2025-04-22","conditions":"Atrial Fibrillation","enrollment":80},{"nctId":"NCT07189091","phase":"PHASE4","title":"CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2025-10-07","conditions":"Critical Care, Intensive Care, Fluid Accumulation, Fluid and Electrolyte Imbalance","enrollment":640},{"nctId":"NCT05867121","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-02","conditions":"Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":102},{"nctId":"NCT05100654","phase":"EARLY_PHASE1","title":"Collaborative Urological Prosthetics Investigation Directive Research Group","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2022-04-22","conditions":"Erectile Dysfunction, Penile Prosthesis Infection","enrollment":800},{"nctId":"NCT06786260","phase":"NA","title":"Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Loma Linda University","startDate":"2026-05","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":30},{"nctId":"NCT05828823","phase":"NA","title":"Incremental Hemodialysis: The TwoPlus Trial","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-02-26","conditions":"End-Stage Kidney Disease","enrollment":350},{"nctId":"NCT07368946","phase":"NA","title":"Phosphate Assessment in Chronic Kidney Disease Patients Study","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-05-09","conditions":"Chronic Kidney Disease (Stage 3-4), Chronic Kidney Disease Mineral and Bone Disorder","enrollment":60},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":"COVID-19, Cardiovascular Diseases","enrollment":372},{"nctId":"NCT06229288","phase":"PHASE3","title":"Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-25","conditions":"Community-acquired Pneumonia","enrollment":326},{"nctId":"NCT07370194","phase":"","title":"Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-28","conditions":"Hyperkalemia","enrollment":6215},{"nctId":"NCT07358065","phase":"NA","title":"Clinical Application of Dynamic Multimodal Analgesia Regimen After Perianal Abscess Surgery","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Putian University","startDate":"2026-01-01","conditions":"Clinical Application of Dynamic Multimodal Analgesia Regimen After Perianal Abscess Surgery","enrollment":135},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":"Chemotherapy Effect","enrollment":198},{"nctId":"NCT06114498","phase":"","title":"Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2023-09-01","conditions":"Heart Failure With Preserved Ejection Fraction, Obesity, Mild, Decompensated Heart Failure","enrollment":240},{"nctId":"NCT07167862","phase":"PHASE4","title":"Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound","status":"NOT_YET_RECRUITING","sponsor":"University of California, Irvine","startDate":"2026-06-15","conditions":"Preeclampsia, Preeclampsia Postpartum, Preeclampsia Severe or Mild","enrollment":96},{"nctId":"NCT06808971","phase":"PHASE2","title":"Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02-28","conditions":"Gastric Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma","enrollment":61},{"nctId":"NCT06761846","phase":"PHASE2","title":"Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-01-17","conditions":"Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma","enrollment":70},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT07355816","phase":"NA","title":"Effect of Different Root Canal Disinfection Procedures on Postoperative Pain","status":"COMPLETED","sponsor":"Cumhuriyet University","startDate":"2023-06-13","conditions":"Pain, Postoperative","enrollment":80},{"nctId":"NCT05441982","phase":"NA","title":"Saccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes","status":"RECRUITING","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2023-09-21","conditions":"Continuous Glucose Monitoring, Oral Glucose Tolerance, Insulin Sensitivity","enrollment":30},{"nctId":"NCT05389995","phase":"NA","title":"Potassium Citrate and Crystal Light Lemonade","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2022-08-01","conditions":"Kidney Stone","enrollment":10},{"nctId":"NCT06426836","phase":"NA","title":"Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2016-08-19","conditions":"Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam","enrollment":300},{"nctId":"NCT05090865","phase":"NA","title":"Dietary Potassium Liberalization in Pre-Dialysis Patients","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2024-01-15","conditions":"Chronic Kidney Disease, Hyperkalemia","enrollment":30},{"nctId":"NCT07244029","phase":"NA","title":"Aescin-Based Herbal Extract (Reparil) for Postoperative Sequelae After Mandibular Third Molar Surgery","status":"RECRUITING","sponsor":"Oman Medical Speciality Board","startDate":"2026-01-01","conditions":"Postoperative Pain, Facial Swelling, Trismus","enrollment":100},{"nctId":"NCT02783859","phase":"PHASE4","title":"Hospitalised Pneumonia With Extended Treatment (HOPE) Study","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2016-06","conditions":"Pneumonia","enrollment":314},{"nctId":"NCT07297732","phase":"NA","title":"A Study to Investigate the Tooth Whitening and Dentin Hypersensitivity Effectiveness of Two Experimental Toothpastes","status":"RECRUITING","sponsor":"HALEON","startDate":"2025-12-15","conditions":"Dentin Hypersensitivity","enrollment":105},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT07341217","phase":"NA","title":"Chemo Brain Prehab Project","status":"NOT_YET_RECRUITING","sponsor":"Dr. Chris Gaffney","startDate":"2026-01-30","conditions":"Colorectal Cancer, Older Adults (60 - 85 Years Old), Physically Inactive","enrollment":86}],"_emaApprovals":[],"_faersSignals":[{"count":181,"reaction":"OFF LABEL USE"},{"count":178,"reaction":"DIARRHOEA"},{"count":159,"reaction":"NAUSEA"},{"count":140,"reaction":"DYSPNOEA"},{"count":138,"reaction":"VOMITING"},{"count":135,"reaction":"FATIGUE"},{"count":124,"reaction":"ACUTE KIDNEY INJURY"},{"count":98,"reaction":"ASTHENIA"},{"count":92,"reaction":"HEADACHE"},{"count":87,"reaction":"HYPOKALAEMIA"}],"administration":{"route":"Oral"},"crossReferences":{"chemblId":"CHEMBL2106975"},"_approvalHistory":[],"publicationCount":352,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"POTASSIUM BICARBONATE","genericName":"POTASSIUM BICARBONATE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T06:14:27.124945+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}